Member Info for Brand

"Wouldn’t that rule us out?"

No.

Thinkingfaceemoji.jpeg

https://www.fiercepharma.com/pharma/johnson-johnson-quietly-works-through-global-overhaul-layoffs-spreading-multiple-countries

"The company is also winding down work of its COVID-19 and HIV vaccines, the latter of which just failed a phase 3 trial. The COVID shot was authorized during the pandemic but failed to gain a foothold in the market due to concerns about blood clots.

Moving forward, J&J plans to focus on pre-exposure prophylaxis to flu, COVID-19, RSV and HRV, the slides show.

The plan was presented to the infectious disease and vaccine team at the Wednesday town hall hosted by Heaton. Merson and Anthony Fernandez, worldwide vice president of vaccines and infectious diseases, contributed virtually."

Lol. What "worries" you about it?

https://www.croiconference.org/preliminary-agenda/

"69 SAFETY AND EFFICACY OF INHALED INTERFERON-?1A (SNG001) IN OUTPATIENTS WITH COVID-19 Prasanna Jagannathan, Kara W. Chew, Mark Giganti, Michael D. Hughes, Mark Main, Phillip Monk, Arzhang C. Javan, Jonathan Z. Li, David A. Wohl, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Upinder Singh, Davey M. Smith, William Fischer Research Group: ACTG A5401 Study Team"

Aether my little sock puppet friend I have no flippin idea. It would appear 'something' is afoot..

For the first time in weeks, and can you imagine that, this board is full of clowns.

Doc, surely a 40min presentation on sng001 in the Activ-2 trial is an update worth looking forward to?

https://www.eurekalert.org/news-releases/979658

Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, will present four oral presentations, two themed discussions, and 23 poster sessions at the Conference on Retroviruses and Opportunistic Infections (CROI 2022), which will be held February 19-22, 2023 in Seattle, Washington. CROI is the premier global HIV research conference and ACTG’s robust presence at the meeting demonstrates its continued leadership in HIV and related fields.

******************

SAFETY AND EFFICACY OF INHALED INTERFERON-ß1A (SNG001) IN OUTPATIENTS WITH COVID-19 (ACTG 5401; Oral Presentation: Tuesday, February 21, 10:29 am PT, Flex C – Level 2) Prasanna Jagannathan, et al.
This study evaluated the safety and efficacy of orally inhaled nebulized interferon-ß1a (SNG001) in a phase 2 randomized controlled trial on the ACTIV-2/A5401 platform.

https://www.raps.org/news-and-articles/news-articles/2023/2/study-10-of-fda-approved-drugs-since-2018-had-pivo

Interesting read

Well that was on the wrong thread. Soz

Yknow what's funny, if you look carefully you can exactly where someone decided to take over this thread w a bunch of accounts.

Tommy - "unless you had some very well established method of proving who would likely suffer severe outcomes"

"Title
Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission- Longitudinal (UNIVERSAL) Study

Description
The global burden of hospital admissions due to respiratory viral illnesses is considerable across the lifespan, with treatment options such as vaccination being mainly supportive. Response to infection is variable, with some experiencing only mild symptoms that do not require admission, whilst others develop a severe response to infection and require higher level care. Rates of complications from respiratory viral infections appear comparable to influenza, suggesting greater attention needs to be focussed on non-influenza respiratory viral illness.

The recent pandemic highlighted the need to link clinical care with research for more rapid translation of new treatment discoveries. The majority of winter pressures facing NHS acute trusts are as a result of acute respiratory viral infection. A better understanding of the natural history of acute respiratory viral infection and recovery will facilitate improved clinical management with the potential to identify options for intervention in those at risk of more severe disease, with resultant health economic benefits."

Waiting for the dam to break ...

https://www.fiercebiotech.com/biotech/biotech-funding-crunch-pours-pressure-partner-promising-meds

It's under "associate director) director of medical affairs" to be exact. Expect it covers mostly the same responsibilities.

Fort Washington as well as the big cities tho gunto. It certainly go unnoticed by potential applicants. But maybe they're trying to poach j&j staff idk.

Have seen that this is indeed one job not several, with the different locations included all having large J&J offices in them. Make of that what you will.

Given the companies newly revealed status as a preferred partner of the UK gov, you have to expect they will be well aware of this document and any aspects relevant to SNG001

Certainly grabs the attention in the newly (re?) published job ads on LinkedIn

Working on the weekend Andy, times must be tough.

Wow. Thank you Titiania - that reads pretty damn well for a "failed" trial, doesn't it?